2016 Kichey Disease | wwnthcttahedtheare.com CATEGORY ARCHIVES: KIDNEY DISEASE Association between plasma endocannabinoids and appetite in hemodialysis patients: A pilot study. Posted on June 24, 2016 by David “Uremia-associated anorexia may be related to altered levels of long chain n-6 and n-3 polyunsaturated fatty acid (PUFA) derived circulating endocannabinoids (EC) and ECsike ‘compounds that are known to mediate appetite, Our study's hypothesis was that such molecules are associated with appetite in patients with end-stage renal disease. A cross- sectional observational study was performed in 20 chronic hemodialysis patients (9 females, 11 males) and 10 healthy female controls in whom appetite was assessed using the Simplified Nutritional Appetite Questionnaire (SNAQ) and blood drawn in the fasting (and when applicable) pre-dialysis state, Blood levels of PUFA and EC were also measured. Higher blood levels of the long chain n-6 fatty acid 20:4n6 (arachidonic acid) and lower levels of the long chain n-3 fatty acid 20:5n3 (eicosapentaenoic acid) were observed in female hemodialysis patients compared to controls. No differences were observed between male and female patients. In female study participants strong correlations between specific EC-like compounds and total SNAQ scores were noted, including with the n-6 PUFA derived linoleoyl ethanolamide (LEA; p=-0.60, P<.01) and the 1-3 PUFA derived docosahexaenoyl ethanolamide (DH-EA; p=0.63, P<.01). The L-EA:DH- EA ratio was most strongly associated with the SNAQ score (p=-0.74, P.001), and its questions associated with appetite (p=-0.69, P<.01) and satiety (9=-0.81, Ps.001). These findings support a link between circulating EC and appetite in hemodialysis patients.” hnttp://wmw.ncbi.nim.nih.gowpubmed/27333956 Ga ) & Be the first of your friends to tke ths. | G+1 | Recommend this on Google Posted in Anorexia, Endocannabinoid System, Kidney Disease | Tagged endocannabinoid system, endocannabinoids, omega-3, omega-6, Polyunsaturated fatty acids (PUFAs) | Leave a reply tpihwuthettalhattnare.comveategorylcney disease! 02016 Kichey Disease | wwnthcttahedtheare.com Anandamide and its metabolites: what are their roles in the kidney? Posted on April 22, 2016 by Davi “Anandamide (AEA) is the N-acyl ethanolamide of arachidonic acid, an agonist of cannabinoid and non-cannabinoid receptors in the body. The kidneys are enriched in AEA and in enzymes that metabolize AEA, but the roles of AEA and its metabolites in the kidney remain poorly understood. This system likely is involved in the regulation of renal blood flow and hemodynamics and of tubular sodium and fluid reabsorption. it may act as a neuromodulator of the renal sympathetic nenous system. AEA and its cyclooxygenase-2 metabolites, the prostamides, in the renal medulla may represent a unique antihypertensive system involved in the long-term control of blood pressure. AEA and its metabolites are also implicated as modulators of inflammation and mediators of signaling in inflammation. AEA and its metabolites may be influential in chronic kidney disease states associated with inflammation and cardiovascular diseases associated with hyperhomocysteinemia. The current knowledge of the roles of AEA and its derivatives highlights the need for further research to define and potentially exploit the role of this endocannabinoid system in the. kidney." http://www. ncbi.nim.nih.gowpubmed/27 100705 a o @ 2 Be the first of your friends to like ths. G+ | Recommend this on Google Posted in Endocannabinoid System, Kidney Disease | Tagged AEA, agonists, anandemide, anti-inflammatory, cannabinoid, cannabinoid receptors, endocannabinoid system | Leave a reply [Role of cannabinoid receptors in renal diseases]. tpihwuthettalhattnare.comveategorylcney disease! 2102016 Kichey Disease | wwnthcttahedtheare.com Posted on March 13, 2016 by David ‘Chronic kidney disease remains a major challenge for public health systems and corresponds to the replacement of renal functional tissue by extracellular matrix proteins such as collagens and fibronectin, There is no efficient treatment to date for chronic kidney disease except nephroprotective strategies. The cannabinoid system and more specifically the cannabinoid receptors 1 (CB1) and 2 (CB2) may represent a new therapeutic target in chronic kidney disease Experimental data obtained in models of diabetes and obesity suggested that CB1 blockade and CB2 stimulation may slow the development of diabetic nephropathy. In human kidneys, CB1 expression is increased in various chronic nephropathies and correlates with renal function. Moreover, endogenous CB1 and CB2 ligands are greatly increased during renal fibrogenesis. A microarray analysis performed in an experimental model of renal fibrosis found that the gene encoding for the CB1 receptor was among the most upregulated genes. We also demonstrated that renal fibrogenesis could be reduced by CB1 inhibition and CB2 stimulation in an experimental model through a direct mechanism involing CB1 on myofibroblasts, which are the major effector cells during renal fibrosis, Therefore, CB1 blockers may represent a novel therapeutic target in chronic kidney disease and diabetes." http://www. ncbi.nim.nih.gowpubmed/26968477 BOQ5 @ ® Be the fist of your friends to tke this, | G#1 | Recommend this on Google Posted in Endocannabinoid System, Kidney Disease | Tagged agonists, antagonists, cannabinoid receptors, CB1, CB2, endocannabinoid system, therapeutic, treatment | Leave a reply Evaluation of the role of the cannabidiol system in an animal model of ischemia/reperfusion tpihwuthettalhattnare.comveategorylcney disease! ano2016 crm Dtee | wtctahadeae com kidney injury. Posted on January 14, 2016 by David “This work aimed to investigate the effects of the administration of cannabidiol in a kidney ischemialreperfusion animal model. The cannabidiol treatment had a protective effect against inflammation and oxidative damage in the kidney ischemialreperfusion model. These effects seemed to be independent of CB1/CB2 receptor activation.” http://www. nebi.nim.nih.gowpubmed/26761477 “In conclusion, the present study suggests that cannabidiol treatment has a protective effect against inflammation and oxidative damage in the utilized kidney ischemialreperfusion model.” http://www. scielo. briscielo. php? script=sci_arttext&pid=S0103-507%2015000400383&ing=en&inrm=iso&ting=en Be the first of your friends to like ths, G21 | Recommend this on Google Posted in Kidney Disease | Tagged anti-inflammatory, antioxidant, cannabii iol system, cannabinoid receptors, cannabinoid system, Cannabi , CBD, Hemp, marijuana, protective, treatment | Leave a reply The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory. Posted on December 15, 2015 by David “The endocannabinoid system (ECS) is a group of neuromodulatory lipids and their receptors, which are widely distributed in mammalian tissues. ECS regulates various cardiovascular, nervous, and immune system functions inside cells. In recent years, there has been a growing body of evidence for the use of synthetic and tpihwuthettalhattnare.comveategorylcney disease! ano2016 Kir Disease | wwathtoidhedtncarecom natural cannabinoids as potential anticancer agents. For instance, the CB1 and CB2 receptors are assumed to play an important role inside the endocannabinoid system. These receptors are abundantly expressed in the brain and fatty tissue of the human body. Despite recent developments in molecular biology, there is still a lack of knowledge about the distribution of CB1 and CB2 receptors in the human kidney and their role in kidney cancer. To address this gap, we explore and demonstrate the role of the endocannabinoid system in renal cell carcinoma (RCC). In this brief overview, we elucidate the therapeutic aspects of the endocannabinoid system for various cancers and explain how this system can be used for treating kidney cancer. Overall, this review provides new insights into cannabinoids’ mechanisms of action in both in vivo and in vitro models, and focuses on recent discoveries in the field http://mww.ncbi.nim.nih.gowpubmed/26654588 a @ 2 Be the first of your friends to tke ths. | G#1 | Recommend this on Google Posted in Cancer, Endocannabinoid System, Kidney Disease, renal cell carcinoma (RCC) | Tagged anticancer, cannabinoid receptors, Cannabinoids, CB(1) and CB(2) receptors, endocannabinoid system, therapeutic | Leave a reply The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases. Posted on August 19, 2015 by David “Endocannabinoids (@CBs) are endogenous lipid ligands that bind to cannabinoid receptors that also mediate the effects of marijuana, The eCB system is comprised of eCBs, anandamide, and 2-arachidonoy! glycerol, their cannabinoid-1 and cannabinoid-2 receptors (CB1 and CB2, respectively), and the enzymes involved in their biosynthesis and degradation tpihwuthettalhattnare.comveategorylcney disease! 5102016 Kichey Disease | wwnthcttahedtheare.com It is present in both the central nervous system and peripheral organs including the kidney. The current review focuses on the role of the eCB system in normal kidney function and various diseases, such as diabetes and obesity, that directly contributes to the development of renal pathologies. Normally, activation of the CB1 receptor regulates renal vascular hemodynamics and stimulates the transport of ions and proteins in different nephron compartments. In various. mouse and rat models of obesity and type 1 and 2 diabetes mellitus, eCBs generated in various renal cells activate CB1 receptors and contribute to the development of oxidative stress, inflammation, and renal fibrosis. These effects can be chronically ameliorated by CB1 receptor blockers. In contrast, activation of the renal CB2 receptors reduces the deleterious effects of these chronic diseases. Because the therapeutic potential of globally acting CB1 receptor antagonists in these conditions is limited due to their neuropsychiatric adverse effects, the recent development of peripherally restricted CB1 receptor antagonists may represent a novel pharmacological approach in treating renal diseases.” hittp://wmw.ncbi.nim.nih.gowpubmed/26280171 a G ® Be the first of your friends to tke ths. | G+1 | Recommend this on Google Posted in Endocannabinoid System, Kidney Disease | Tagged 2-AG, agonists, anandemide, antagonists, cannabinoid receptors, Cannabinoids, cannabis, CB(1) and CB(2) receptors, endocannabinoid system, endocannabinoids, marijuana, therapeutic | Leave a reply Novel Triazolopyrimidine- Derived Cannabinoid Receptor 2 Agonists As Potential Treatment for Inflammatory Kidney tpihwuthettalhattnare.comveategorylcney disease! eno2ma0%6 Kichey Disease | wwnthcttahedtheare.com Diseases. Posted on August 1, 2015 by David “The cannabinoid receptor 2 (CB2) system is described to modulate various pathological conditions, including inflammation and fibrosis A series of new heterocyclic small-molecule CB2 receptor agonists were identified from a high-throughput screen A significant depletion of the three measured kidney markers indicated a protective role of (CB2 receptor activation toward inflammatory kidney damage, Compound 39 was also protective in a mode! of renal fibrosis. Oral treatment with 39 at 3 mg kg-1 per day significantly decreased the amount of fibrosis, by ~40 % which was induced by unilateral ureter obstruction.” http://www. ncbi.nim.nih.gowpubmed/26228928 a) & Be the first of your friends to like ths, Recommend this on Google Posted in Endocannabinoid System, Kidney Disease | Tagged agonists, anti- inflammatory, cannabinoid receptors, Cannabinoids, CB2, protective, treatment | Leave a reply The Endocannabinoid System in Renal Cell: Regulation of Na+ Transport by CB1 Receptors Through Distinct Cell Signaling Pathways. Posted on July 17, 2015 by David “The function of the endocannabinoid system (ECS) in the renal tissue is not completely understood tpihwuthettalhattnare.comveategorylcney disease! mo2016 Kiney Disease | wwtcttaheatheare.com We studied the effect of compounds modulating the activity of cannabinoid CB receptors on the active reabsorption of Na+ in LLC-PK{1 cells. CONCLUSION AND IMPLICATIONS: ECS is expressed in LLC-PK1 cells. Both TRPV1 and CB1 regulate (Na++K+)-ATPase activity in these cells, and are modulated by lipid and peptide CB1 ligands, which act via different signaling pathways” hittp://www.ncbi.nim.nih.gowpubmed/25537261 a “ @ Be the first of your friends to tke ths. | G+1 | Recommend this on Google Posted in Endocannabinoid System, Kidney Disease, Uncategorized | Tagged cannabinoid, cannabinoid receptors, Cannabinoids, CB1, endocannabinoid system | Leave a reply The endocannabinoid system in renal cell: Regulation of Na+ transport by CB1 receptors through distinct cell signaling pathways. Posted on July 17, 2015 by David “The function of the endocannabinoid system (ECS) in the renal tissue is not completely understood. Kidney function is closely related to ion reabsorption in the proximal tubule, the nephron segment responsible for the reabsorption of 70- 80% of the filtrate. We studied the effect of compounds modulating the activity of cannabinoid CB receptors on the active reabsorption of Nat in LLC-PK1 cells. CONCLUSION AND IMPLICATIONS: ECS is expressed in LLC-PK1 cells. Both CB1 and TRPV1 regulate (Na+ +K+ ATPase activity in these cells, and are modulated by lipid and peptide CB1 ligands, which act via different signaling pathways.’ http://w. ncbi.nim.nih,gowpubmed/26177675 tpihwuthettalhattnare.comveategorylcney disease! ano2016 Kichey Disease | wwnthcttahedtheare.com 2 Be the fist of your friends to tke this, G+ | Recommend this on Google Posted in Endocannabinoid System, Kidney Disease, Uncategorized | Tagged cannabinoid, cannabinoid receptors, Cannabinoids, CB1, endocannabinoid system | Leave a reply Renal Effects of Chronic Pharmacological Manipulation of CB2 in Rats with Diet Induced Obesity. Posted on April 2, 2015 by David “In diabetic nephropathy CB2 agonism reduces albuminuria and podocyte loss; however the role of CB2 in obesity-related nephropathy is unknown. The aim of this study was to determine the role of CB2 in a model of diet-induced obesity (DIO). Tis study demonstrates that while agonism of CB2 with AM1241 treatment for six weeks does not reduce weight gain in obese rats, it leads to improvements in obesity related renal dysfunction.” http://www. ncbi.nim.nih.gowpubmed/25537025 “Alexandros Makriyannis is a professor in the Department of Medicinal Chemistry at Northeastem University, where his research group has synthesized many new compounds with cannabinoid activity. * AM-1241 — a potent and selective analgesic CB2 agonist with a Kj of 3.4nM at CB2 and 80x selectivity over CB.” http://en wikipedia. org/wiki/List_of_ AM_cannabinoids a & Be the fist of your friends to tke this. | G#1 | Recommend this on Google tpihwuthettalhattnare.comveategorylcney disease! anoarreo% Kiney Disease | wwtcttaheatheare.com Posted in Kidney Disease, Obesity | Tagged agonism, agonists, cannabinoid, cannabinoid receptors, CB2, treatment | Leave a reply tpihwuthettalhattnare.comveategorylcney disease! so10